## 1,3,5-Triallyl Isocyanurate: A Versatile Building Block for Research
**1,3,5-Triallyl isocyanurate (TAIC)** is a cyclic organic compound with the molecular formula C12H15N3O3. It's a white, crystalline solid that is readily soluble in organic solvents.
**Why is it important for research?**
TAIC's importance lies in its unique combination of properties, making it a versatile building block for various applications, particularly in research:
**1. Reactivity:**
* **Crosslinking agent:** TAIC is a highly reactive monomer that undergoes free radical polymerization. This allows it to form crosslinked polymers with various other monomers, resulting in materials with improved mechanical properties, thermal stability, and chemical resistance.
* **Photopolymerization:** TAIC can also participate in photopolymerization reactions, enabling the development of UV-curable resins and coatings.
* **Ring-opening polymerization:** TAIC can undergo ring-opening polymerization to form polymers with unique properties, such as biodegradability and biocompatibility.
**2. Applications in Research:**
* **Materials science:** TAIC is used in the development of various materials, including:
* **Polymers:** Thermosets, adhesives, coatings, composites, and sealants.
* **Nanocomposites:** By incorporating TAIC into nanomaterials, researchers can enhance their properties and develop advanced materials with unique functionalities.
* **Biomedical research:** TAIC's biocompatibility and biodegradability make it suitable for applications in:
* **Biodegradable polymers:** Used for drug delivery, tissue engineering, and medical implants.
* **Hydrogels:** Used in wound dressings, bioadhesives, and controlled drug release systems.
* **Photochemistry and photopolymerization:** TAIC's photoreactivity makes it ideal for studying photochemical reactions, developing photocurable resins, and exploring new photopolymerization techniques.
**3. Other Properties:**
* **Thermal stability:** TAIC possesses good thermal stability, making it useful for high-temperature applications.
* **Hydrolytic stability:** TAIC is relatively resistant to hydrolysis, enhancing its durability in various environments.
**Overall, 1,3,5-triallyl isocyanurate's unique properties and versatility make it a valuable tool in various research fields, contributing to advancements in materials science, biomedical engineering, and other areas.**
| ID Source | ID |
|---|---|
| PubMed CID | 13931 |
| CHEMBL ID | 1327450 |
| CHEBI ID | 195263 |
| SCHEMBL ID | 28662 |
| MeSH ID | M0458360 |
| Synonym |
|---|
| triallyl isocyanurate (500 ppm bht as inhibitor) |
| 1,3,5-triallylisocyanurate |
| s-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-triallyl- |
| ai3-60290 |
| taic |
| isocyanuric acid triallyl ester |
| 1,3,5-triallyl-1,3,5-triazine-2,4,6(1h,3h,5h)-trione |
| triallylisocyanurate |
| einecs 213-834-7 |
| brn 0225482 |
| nsc 11692 |
| 1,3,5-triallylisocyanuric acid |
| diak 7 |
| s-triazine-2,4,6(1h,3h,5h)-trione, triallyl- |
| 1,3,5-triallyl isocyanurate |
| ccris 6105 |
| isocyanuric acid, triallyl ester |
| 1,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tri-2-propenyl- |
| nsc-11692 |
| 1,5-triallylisocyanuric acid |
| 1,5-triallyl isocyanurate |
| nsc11692 |
| s-triazine-2,6(1h,3h,5h)-trione, 1,3,5-triallyl- |
| triallyl isocyanurate |
| 1025-15-6 |
| 1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tri-2-propenyl- |
| NCGC00091064-01 |
| 1,3,5-triallyl-1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 98% |
| NCI60_000389 |
| 1,3,5-triallyl-1,3,5-triazinane-2,4,6-trione |
| MLS001056238 |
| smr001216600 |
| I0279 |
| CHEBI:195263 |
| 1,3,5-triprop-2-enyl-1,3,5-triazaperhydroine-2,4,6-trione |
| 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione |
| A800579 |
| NCGC00091064-02 |
| 1,3,5-triallyl-[1,3,5]triazinane-2,4,6-trione |
| ec 213-834-7 |
| p48obj1g11 , |
| 1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tri-2-propen-1-yl- |
| unii-p48obj1g11 |
| NCGC00257824-01 |
| cas-1025-15-6 |
| tox21_200270 |
| dtxsid0026175 , |
| dtxcid906175 |
| 1,3,5-tri-2-propenyl-1,3,5-triazine-2,4,6(1h,3h,5h)-trione |
| FT-0627404 |
| AKOS015904043 |
| SCHEMBL28662 |
| 1,3,5-tris-2'-propenylisocyanuric acid |
| triallyl-1,3,5-triazine-2,4,6(1h,3h,5h)-trione |
| triallylisocyanuric acid |
| CHEMBL1327450 |
| KOMNUTZXSVSERR-UHFFFAOYSA-N |
| triallyl-s-triazine-2,4,6(1h,3h,5h)-trione |
| triallyl 1,3,5-triazine-2,4,6(1h,3h,5h)-trione |
| perkalink 301 |
| 1,3,5-triallyl-s-triazine-2,4,6(1h,3h,5h)-trione |
| 1,3,5-triallyl-1,3,5-triazinane-2,4,6-trione # |
| triallyl-s-triazine-2,4,6-(1h,3h,5h)-trione |
| mfcd00006554 |
| solar photovoltaic cell encapsulation film |
| thermoplastic plastics and resins |
| triallyl isocyanurate (stabilized with bht) |
| D70965 |
| BCP25975 |
| 1,3,5-triallyl-1,3,5-triazinane-2,4,6-trione;isocyanuric acid triallyl ester |
| AS-15234 |
| CS-W014106 |
| Q27286126 |
| Class | Description |
|---|---|
| triazines | Compounds based on a triazine skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 79.3809 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.9272 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 9.4200 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 60.9441 | 0.0002 | 21.2231 | 8,912.5098 | AID743042 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 43.5024 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 48.4096 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 19.4318 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 74.9780 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 18.8336 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleoplasm | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nuclear body | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| chromatin | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| nucleus | Nuclear receptor ROR-gamma | Homo sapiens (human) |
| plasma membrane | Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) |
| plasma membrane | Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||